Stage one
Immediate-release coating
The outer coating contains 22% of the dose. It dissolves on contact and provides the initial effect within the first hour.
Active ingredient: methylphenidate hydrochloride · Equivalent UK brands: Matoride XL · Xaggitin XL · Delmosart XL · Xenidate XL · Affenid XL
Concerta XL (methylphenidate) is the most-prescribed long-acting methylphenidate in the UK. A once-daily tablet using a gradual-release pump system that delivers a steady release across most of the working day.
Concerta XL uses an osmotic-controlled release oral system. The tablet is engineered with three working parts.
The outer coating contains 22% of the dose. It dissolves on contact and provides the initial effect within the first hour.
Water is drawn through a semipermeable membrane into the tablet core. This pressurises the drug compartment and pushes the medication out steadily.
The medication exits through a precisely sized laser-drilled hole. This produces a gradual release across roughly ten to twelve hours.
The empty tablet shell passes through your digestive system intact. Some people notice this. It is normal and does not mean the medication has not been absorbed.
Methylphenidate works by blocking the reuptake of dopamine and norepinephrine in the brain. Both neurotransmitters are involved in attention, motivation and impulse control. By blocking their reuptake, methylphenidate increases their availability in the synaptic gap, which translates into improved focus and reduced impulsivity for most people with ADHD.
Concerta XL is a gradual-release formulation that delivers the same active molecule but with a release profile engineered to last most of a working day from one morning dose. Onset is within thirty to sixty minutes, the medication builds gradually, holds an effective range across the middle of the day, and tapers gently into the evening.
Equivalent generic brands. Matoride XL, Xaggitin XL, Delmosart XL, Xenidate XL and Affenid XL all use the same gradual-release pump as Concerta XL. They are pharmacologically equivalent. Pharmacies may dispense any of them depending on availability. ADHDose models the same release profile because the underlying PK is identical.
Concerta XL is one of several methylphenidate formulations prescribed in the UK. They share an active molecule but differ in how it is released.
UK Concerta XL titration typically starts at 18mg and increases in defined steps to 27mg, 36mg and 54mg, based on response. Each dose level is usually maintained for two to four weeks before review. Titration can take several months depending on availability of appointments and how cleanly the dose-response settles.
Available UK doses: 18mg, 27mg, 36mg, 54mg.
Most people take Concerta XL first thing in the morning. The combination of a thirty- to sixty-minute onset and a ten- to twelve-hour duration means the dose timing decides where the medication's effective range sits in your day. Taking it at 6am rather than 9am moves the entire profile three hours earlier. ADHDose models that exact relationship for your specific dose.
Concerta XL can be taken with or without food. Tablets must be swallowed whole — do not crush, chew or split. Splitting the tablet breaks the gradual-release mechanism and effectively converts the dose into an immediate-release dump, which is both ineffective and unsafe at higher dose levels.
ADHDose models your Concerta XL release using the published pharmacokinetic profile, calibrated to your dose, your timing and your individual metabolism. The app translates that into real-time guidance through your day, calculates a personalised wind-down window, and exports a Clinician Summary PDF in NHS prescriber format for review appointments.
Concerta XL releases gradually through the day rather than spiking. The exact build-up depends on your dose, your metabolism and the time you took it. ADHDose calibrates that picture for your prescription and updates it through your day.
The app reads your prescription, learns your individual response and tells you where you are in your medication day, minute by minute. The Clinician Summary export pulls 28 days of patterns into NHS prescriber format for your reviews.
Most people tolerate Methylphenidate well, especially after the first few weeks. Here are the patterns worth noticing — and the ones that warrant a call to your prescriber.
Most ease in the first two to four weeks. Logging them daily helps you and your prescriber decide whether they are settling or sticking.
Not emergencies, but worth bringing up. ADHDose tags recurring patterns automatically in your daily logs.
Rare, but worth knowing. If you see any of these, contact your prescriber rather than stopping on your own.
The first weeks of Methylphenidate have a recognisable shape. Knowing what is normal at each stage stops you reading too much into a single bad day.
Most people feel something within the first hour of the first dose. The first few days often involve small wobbles — appetite changes, sleep shifts, occasional headaches. None of this is unusual. Daily logging helps separate first-dose nerves from real side effect patterns.
Side effects from days one to three usually start to ease. The dose-response becomes more predictable. Track focus, sleep and energy daily. This is the data your prescriber wants at your first review.
Most UK and US protocols schedule the first review around week two or four. Your prescriber will ask about effect, side effects, sleep and appetite. Bringing tracked data — rather than relying on memory — turns the review from vague impressions into something concrete.
If the first dose is not quite right, your prescriber will adjust upward in defined steps. Each step is usually held for two to four weeks before the next adjustment. The same daily logging continues.
Once the dose is settled, reviews shift to every six to twelve months. Daily logging becomes lighter — focus and sleep are usually enough. The Clinician Summary export gives prescribers a 28-day window of evidence at each review.
ADHDose makes the milestone view concrete. Daily logs of focus, sleep, energy and side effects across the titration window show the trajectory clearly — to you, and to your prescriber when review day arrives.